Literature DB >> 35347397

Successful allogeneic bone marrow transplantation in a case of variant acute promyelocytic leukemia with ZBTB16-RARA.

Suguru Morimoto1, Tadakazu Kondo2, Tomohiro Taya1, Hidemasa Matsuo3, Yukako Teramoto4, Chisaki Mizumoto1, Junya Kanda1, Kouhei Yamashita1, Akifumi Takaori-Kondo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35347397     DOI： 10.1007/s00277-022-04825-8

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  8 in total

Review 1.  Current standard treatment of adult acute promyelocytic leukaemia.

Authors:  Francesco Lo-Coco; Laura Cicconi; Massimo Breccia
Journal:  Br J Haematol       Date:  2015-12-21       Impact factor: 6.998

2.  Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARalpha and NPM-RARalpha.

Authors:  G X Cheng; X H Zhu; X Q Men; L Wang; Q H Huang; X L Jin; S M Xiong; J Zhu; W M Guo; J Q Chen; S F Xu; E So; L C Chan; S Waxman; A Zelent; G Q Chen; S Dong; J X Liu; S J Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

3.  Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid.

Authors:  K Kitamura; S Hoshi; M Koike; H Kiyoi; H Saito; T Naoe
Journal:  Br J Haematol       Date:  2000-03       Impact factor: 6.998

4.  Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Groupe Français de Cytogénétique Hématologique, Groupe de Français d'Hematologie Cellulaire, UK Cancer Cytogenetics Group and BIOMED 1 European Community-Concerted Action "Molecular Cytogenetic Diagnosis in Haematological Malignancies".

Authors:  D Grimwade; A Biondi; M J Mozziconacci; A Hagemeijer; R Berger; M Neat; K Howe; N Dastugue; J Jansen; I Radford-Weiss; F Lo Coco; M Lessard; J M Hernandez; E Delabesse; D Head; V Liso; D Sainty; G Flandrin; E Solomon; F Birg; M Lafage-Pochitaloff
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

5.  A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF/RARA gene rearrangements.

Authors:  D Sainty; V Liso; A Cantù-Rajnoldi; D Head; M J Mozziconacci; C Arnoulet; L Benattar; S Fenu; M Mancini; E Duchayne; F X Mahon; N Gutierrez; F Birg; A Biondi; D Grimwade; M Lafage-Pochitaloff; A Hagemeijer; G Flandrin
Journal:  Blood       Date:  2000-08-15       Impact factor: 22.113

6.  PLZF-RAR alpha fusion proteins generated from the variant t(11;17)(q23;q21) translocation in acute promyelocytic leukemia inhibit ligand-dependent transactivation of wild-type retinoic acid receptors.

Authors:  Z Chen; F Guidez; P Rousselot; A Agadir; S J Chen; Z Y Wang; L Degos; A Zelent; S Waxman; C Chomienne
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-01       Impact factor: 11.205

7.  Development of real-time quantitative polymerase chain reaction assays to track treatment response in retinoid resistant acute promyelocytic leukemia.

Authors:  Jelena V Jovanovic; Kristian Rennie; Dominic Culligan; Andrew Peniket; Anne Lennard; Justin Harrison; Paresh Vyas; David Grimwade
Journal:  Front Oncol       Date:  2011-10-25       Impact factor: 6.244

8.  Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia.

Authors:  D Grimwade; P Gorman; E Duprez; K Howe; S Langabeer; F Oliver; H Walker; D Culligan; J Waters; M Pomfret; A Goldstone; A Burnett; P Freemont; D Sheer; E Solomon
Journal:  Blood       Date:  1997-12-15       Impact factor: 22.113
  8 in total
  1 in total

1.  Hyperthermia promotes degradation of the acute promyelocytic leukemia driver oncoprotein ZBTB16/RARα.

Authors:  Qian-Qian Wang; Liaqat Hussain; Pei-Han Yu; Chang Yang; Chen-Ying Zhu; Ya-Fang Ma; Si-Chun Wang; Tao Yang; Yuan-Yuan Kang; Wen-Juan Yu; Yasen Maimaitiyiming; Hua Naranmandura
Journal:  Acta Pharmacol Sin       Date:  2022-10-10       Impact factor: 7.169
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.